Nkarta appoints Nadir Mahmood as President, promotes David Shook to CMO

Nkarta, Inc.

Nadir Mahmood, former Nkarta CFO and Rezo CEO, appointed President effective July 29, 2024; shares leadership with CEO Paul Hastings.
David Shook promoted to Chief Medical Officer, Head of R&D, overseeing clinical development, regulatory, and translational science.
James Trager steps down as Chief Scientific Officer due to personal reasons, transitions to special advisory role.
Mahmood receives $530K base salary, option for 550K shares vesting over time, 50% target bonus; severance terms included.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Nadir Mahmood

President

NKTX · Nkarta, Inc.

Effective: 2024-07-29
Filed: July 16, 2024, 7:59 PM ET

On July 10, 2024, Nkarta, Inc.'s (the “Company”) Board of Directors (the “Board”) appointed Nadir Mahmood, Ph.D. as the Company’s President, effective July 29, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Nadir Mahmood was appointed as President at Nkarta, Inc..

Action: appointed
Role: President

Exact text from the filing

On July 10, 2024, Nkarta, Inc.'s (the “Company”) Board of Directors (the “Board”) appointed Nadir Mahmood, Ph.D. as the Company’s President, effective July 29, 2024.

View on SEC.gov

Nkarta, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-083761

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.